Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

An Immunogenic Model of KRAS-Mutant Lung Cancer Enables Evaluation of Targeted Therapy and Immunotherapy Combinations
Jesse Boumelha, Sophie de Carné Trécesson, Emily K. Law, et al.
Cancer Research (2022) Vol. 82, Iss. 19, pp. 3435-3448
Open Access | Times Cited: 56

Showing 1-25 of 56 citing articles:

Antibodies against endogenous retroviruses promote lung cancer immunotherapy
Kevin W. Ng, Jesse Boumelha, Katey S.S. Enfield, et al.
Nature (2023) Vol. 616, Iss. 7957, pp. 563-573
Open Access | Times Cited: 153
Advances and challenges in the treatment of lung cancer
Yuting Li, Bingshuo Yan, Shiming He
Biomedicine & Pharmacotherapy (2023) Vol. 169, pp. 115891-115891
Open Access | Times Cited: 127
Exploiting the therapeutic implications of KRAS inhibition on tumor immunity
Míriam Molina‐Arcas, Julian Downward
Cancer Cell (2024) Vol. 42, Iss. 3, pp. 338-357
Open Access | Times Cited: 46
The role of APOBEC3B in lung tumor evolution and targeted cancer therapy resistance
Deborah R. Caswell, Philippe Gui, Manasi K. Mayekar, et al.
Nature Genetics (2023) Vol. 56, Iss. 1, pp. 60-73
Open Access | Times Cited: 41
Hematopoietic aging promotes cancer by fueling IL-1⍺–driven emergency myelopoiesis
Matthew D. Park, Jessica Le Bérichel, Pauline Hamon, et al.
Science (2024) Vol. 386, Iss. 6720
Open Access | Times Cited: 25
Combinatorial strategies to target RAS-driven cancers
Naiara Perurena, Lisa Situ, Karen Cichowski
Nature reviews. Cancer (2024) Vol. 24, Iss. 5, pp. 316-337
Closed Access | Times Cited: 22
Targeting KRAS: from metabolic regulation to cancer treatment
Yanyan Shi, Huiling Zheng, Tianzhen Wang, et al.
Molecular Cancer (2025) Vol. 24, Iss. 1
Open Access | Times Cited: 3
Tertiary lymphoid structures and cancer immunotherapy: From bench to bedside
Florent Peyraud, Jean‐Philippe Guégan, Lucile Vanhersecke, et al.
Med (2025) Vol. 6, Iss. 1, pp. 100546-100546
Closed Access | Times Cited: 2
Drugging the Undruggable: Advances on RAS Targeting in Cancer
Míriam Molina‐Arcas, Amit Samani, Julian Downward
Genes (2021) Vol. 12, Iss. 6, pp. 899-899
Open Access | Times Cited: 68
Human APOBEC3B promotes tumor development in vivo including signature mutations and metastases
Cameron Durfee, Nuri A. Temiz, Rena Levin-Klein, et al.
Cell Reports Medicine (2023) Vol. 4, Iss. 10, pp. 101211-101211
Open Access | Times Cited: 32
Cancer immune evasion through KRAS and PD-L1 and potential therapeutic interventions
Alex Watterson, Matthew A. Coelho
Cell Communication and Signaling (2023) Vol. 21, Iss. 1
Open Access | Times Cited: 23
Exploiting Tertiary Lymphoid Structures to Stimulate Antitumor Immunity and Improve Immunotherapy Efficacy
Giulia Petroni, Serena Pillozzi, Lorenzo Antonuzzo
Cancer Research (2024) Vol. 84, Iss. 8, pp. 1199-1209
Open Access | Times Cited: 12
Recent progress in targeting KRAS mutant cancers with covalent G12C-specific inhibitors
Lala S. Rathod, Pratap S. Dabhade, Santosh N. Mokale
Drug Discovery Today (2023) Vol. 28, Iss. 5, pp. 103557-103557
Closed Access | Times Cited: 18
Cancer cells impair monocyte-mediated T cell stimulation to evade immunity
Anais Elewaut, Guillem Estivill, Felix Bayerl, et al.
Nature (2024)
Open Access | Times Cited: 7
APOBEC Mutagenesis in Cancer Development and Susceptibility
Alexandra Dananberg, Josefine Striepen, Jacob S Rozowsky, et al.
Cancers (2024) Vol. 16, Iss. 2, pp. 374-374
Open Access | Times Cited: 6
Durable responses to alectinib in murine models of EML4-ALK lung cancer requires adaptive immunity
Emily K. Kleczko, Trista K. Hinz, Teresa T. Nguyen, et al.
npj Precision Oncology (2023) Vol. 7, Iss. 1
Open Access | Times Cited: 14
DNA Deamination Is Required for Human APOBEC3A-Driven Hepatocellular Carcinoma In Vivo
Jordan A. Naumann, Prokopios P. Argyris, Michael A. Carpenter, et al.
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 11, pp. 9305-9305
Open Access | Times Cited: 14
Facts and Hopes on RAS Inhibitors and Cancer Immunotherapy
Jesse Boumelha, Míriam Molina‐Arcas, Julian Downward
Clinical Cancer Research (2023) Vol. 29, Iss. 24, pp. 5012-5020
Open Access | Times Cited: 14
CRISPR-Cas9 screening identifies KRAS-induced COX-2 as a driver of immunotherapy resistance in lung cancer
Jesse Boumelha, Andrea de Castro, Nourdine Bah, et al.
Cancer Research (2024) Vol. 84, Iss. 14, pp. 2231-2246
Open Access | Times Cited: 5
Structural perspectives on recent breakthrough efforts toward direct drugging of RAS and acquired resistance
Jameela Lokhandwala, Tracess Smalley, Timothy H. Tran
Frontiers in Oncology (2024) Vol. 14
Open Access | Times Cited: 5
Integrative multi-omics analysis for identifying novel therapeutic targets and predicting immunotherapy efficacy in lung adenocarcinoma
Zi‐Lu Chen, Kun Mei, Fraser Elisabeth Tan, et al.
Cancer Drug Resistance (2025)
Open Access
Cancer evolution: from Darwin to the Extended Evolutionary Synthesis
Thierry Savy, Lucy Flanders, Thaneswari Karpanasamy, et al.
Trends in cancer (2025)
Open Access
Kras Ctdna Detection in Patients with Resectable Lung Adenocarcinoma
Meghan L. De Meo, Joseph Seitlinger, Roni Rayes, et al.
(2025)
Closed Access
Immunotherapy in advanced, KRAS G12C-mutant non-small-cell lung cancer: current strategies and future directions
Nadia Ghazali, Marina Chiara Garassino, Natasha B. Leighl, et al.
Therapeutic Advances in Medical Oncology (2025) Vol. 17
Open Access
Tissue-specific properties of type 1 dendritic cells in lung cancer: implications for immunotherapy
Laura Rodríguez, Roberto M. Amadio, Giulia Maria Piperno, et al.
Journal for ImmunoTherapy of Cancer (2025) Vol. 13, Iss. 3, pp. e010547-e010547
Open Access
Page 1 - Next Page

Scroll to top